---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278408190.md"
description: "Relmada Therapeutics shares are trading higher after the company reported 12-month interim data from its ongoing Phase 2 trial evaluating NDV-01 in patients with high-risk non-muscle invasive bladder cancer. Also, the company announced a $160 million private placement."
datetime: "2026-03-09T14:12:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278408190.md)
  - [en](https://longbridge.com/en/news/278408190.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278408190.md)
---

# 

Relmada Therapeutics shares are trading higher after the company reported 12-month interim data from its ongoing Phase 2 trial evaluating NDV-01 in patients with high-risk non-muscle invasive bladder cancer. Also, the company announced a $160 million private placement.

### Related Stocks

- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [RLMD.US](https://longbridge.com/en/quote/RLMD.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)

## Related News & Research

- [CRISPR Therapeutics Touts “Second Phase” After Casgevy, Eyes 6 Data Readouts in 6–12 Months](https://longbridge.com/en/news/282582813.md)
- [Should Positive Elsunersen Data And Relutrigine Priority Review Shift the Narrative for Praxis (PRAX) Investors?](https://longbridge.com/en/news/282419526.md)
- [Revolution Medicines Says Daraxonrasib Shows Improvement In Survival In Late-Stage Pancreatic Cancer Study](https://longbridge.com/en/news/282550417.md)
- [Avant Brands Reports Q1 2026 Results Highlighted by 37% Growth in Recreational Revenue | AVTBF Stock News](https://longbridge.com/en/news/282741678.md)
- [Revolution Medicines' experimental cancer pill helps improve survival in late-stage study](https://longbridge.com/en/news/282540793.md)